Vistin Pharma ASA (FRA:VP4)

Vistin Pharma ASA Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	78.06	62.75	45.6	-4.72	24.87	-96.96
Depreciation & Amortization	21.57	19.03	17.35	12.28	10.61	9.62
Other Operating Activities	22.02	17.7	12.92	-1.29	7.13	-27.31
Change in Accounts Receivable	-3.12	-3.12	12.14	-20.81	-12.76	2.16
Change in Inventory	3.51	3.51	3.28	-40.54	-11.12	-7.68
Change in Other Net Operating Assets	-42.36	7.99	-0.69	44.57	-5.05	-25.56
Operating Cash Flow	79.69	107.86	90.59	-10.51	13.68	-145.73
Operating Cash Flow Growth	-20.20%	19.06%	-	-	-	-
Capital Expenditures	-14.79	-40.8	-17.9	-64.29	-31.94	-53.1
Other Investing Activities	0.51	0.51	0.22	0.03	0.27	1.73
Investing Cash Flow	-14.28	-40.3	-17.68	-64.26	-31.68	-51.38
Short-Term Debt Issued	-	-	-	45.14	-	-
Total Debt Issued	-	-	-	45.14	-	-
Short-Term Debt Repaid	-	-	-45.14	-	-	-
Long-Term Debt Repaid	-	-1.2	-0.9	-2.59	-0.84	-0.43
Total Debt Repaid	-1.2	-1.2	-46.05	-2.59	-0.84	-0.43
Net Debt Issued (Repaid)	-1.2	-1.2	-46.05	42.55	-0.84	-0.43
Common Dividends Paid	-77.6	-77.59	-	-	-22.17	-44.35
Other Financing Activities	11.16	-2.19	-2.1	-2.09	-0.29	-0.75
Financing Cash Flow	-67.65	-80.97	-48.14	40.46	-23.3	-45.53
Miscellaneous Cash Flow Adjustments	-0	-0	0	0	0	-0
Net Cash Flow	-2.24	-13.41	24.77	-34.31	-41.29	-242.64
Free Cash Flow	64.9	67.05	72.69	-74.8	-18.26	-198.83
Free Cash Flow Growth	16.37%	-7.75%	-	-	-	-
Free Cash Flow Margin	14.26%	15.61%	16.58%	-24.54%	-6.55%	-78.31%
Free Cash Flow Per Share	1.46	1.51	1.64	-1.69	-0.41	-4.48
Cash Interest Paid	2.19	2.19	2.1	2.09	0.29	0.75
Levered Free Cash Flow	19.82	36.75	54.19	-81.62	-30.41	-44.79
Unlevered Free Cash Flow	19.82	38.21	55.61	-80.28	-30.19	-44.28
Change in Working Capital	-41.97	8.38	14.73	-16.78	-28.92	-31.09

Source: S&P Global Market Intelligence. Standard template. Financial Sources.